Shanghai - Delayed Quote CNY

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (603392.SS)

Compare
68.99
+0.73
+(1.07%)
At close: 3:00:06 PM GMT+8
Loading Chart for 603392.SS
DELL
  • Previous Close 68.26
  • Open 68.00
  • Bid 68.99 x --
  • Ask 69.00 x --
  • Day's Range 67.57 - 69.00
  • 52 Week Range 47.62 - 89.89
  • Volume 2,279,805
  • Avg. Volume 4,066,717
  • Market Cap (intraday) 87.281B
  • Beta (5Y Monthly) 2.26
  • PE Ratio (TTM) --
  • EPS (TTM) -0.23
  • Earnings Date --
  • Forward Dividend & Yield 0.32 (0.47%)
  • Ex-Dividend Date Jun 3, 2024
  • 1y Target Est --

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. research, develops, produces, distributes, and sells infectious disease diagnostic reagents and vaccines in China and internationally. The company provides chemiluminescence series, assembly line series, nucleic acid series, dry type fluorescent immunoassay, and fully automatic blood type analyzer and reagents; ELISA kits; rapid diagnosis; bole series; and supporting reagents. The company was founded in 1991 and is headquartered in Beijing, China.

www.ystwt.com

3,843

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 603392.SS

View More

Performance Overview: 603392.SS

Trailing total returns as of 1/16/2025, which may include dividends or other distributions. Benchmark is

.

YTD Return

603392.SS
4.25%
SSE Composite Index
5.03%

1-Year Return

603392.SS
5.35%
SSE Composite Index
12.12%

3-Year Return

603392.SS
32.91%
SSE Composite Index
8.10%

5-Year Return

603392.SS
1,456.11%
SSE Composite Index
4.72%

Compare To: 603392.SS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 603392.SS

View More

Valuation Measures

As of 1/15/2025
  • Market Cap

    86.36B

  • Enterprise Value

    81.79B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    34.66

  • Price/Book (mrq)

    6.95

  • Enterprise Value/Revenue

    32.85

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -11.81%

  • Return on Assets (ttm)

    -1.54%

  • Return on Equity (ttm)

    -2.26%

  • Revenue (ttm)

    2.49B

  • Net Income Avi to Common (ttm)

    -294.04M

  • Diluted EPS (ttm)

    -0.23

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    5.5B

  • Total Debt/Equity (mrq)

    2.21%

  • Levered Free Cash Flow (ttm)

    28.87M

Research Analysis: 603392.SS

View More

People Also Watch